Iovance Biotherapeutics, Inc.
IOVA
Classifica tra le azioni
#2761
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Prezzo delle azioni
$14.72
Ultima sincronizzazione: 2026-10-21
Capitalizzazione di mercato
$6.67B
Variazione (1 giorno)
-0.98%
Variazione (1 anno)
584.42%
Paese
US
Scambia Iovance Biotherapeutics, Inc. (IOVA)
Categoria
Healthcare
Storico del prezzo dell'azione per Iovance Biotherapeutics, Inc. (IOVA)
Prezzo di chiusura più alto: $14.12 il 2026-10-01
Prezzo di chiusura più basso: $103.55 il 2010-10-01
Prezzo di chiusura più basso: $103.55 il 2010-10-01
Storico del prezzo dell'azione di Iovance Biotherapeutics, Inc. dal 2010 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | 98.68% |
| 2025 | -69.46% |
| 2024 | 9.49% |
| 2023 | 11.39% |
| 2022 | -64.95% |
| 2021 | -60.13% |
| 2020 | 75.74% |
| 2019 | 190.57% |
| 2018 | 7.35% |
| 2017 | 24.29% |
| 2016 | -11.09% |
| 2015 | 11.54% |
| 2014 | -28.26% |
| 2013 | -59.07% |
| 2012 | -76.79% |
| 2011 | -13.84% |
| 2010 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $755.78 | 7.42% |
CH
|
